Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation

[1]  J. Cohnheim,et al.  Lectures on general pathology , 2013 .

[2]  H. Findley,et al.  Targeting the MDM2–p53 interaction as a therapeutic strategy for the treatment of cancer , 2010 .

[3]  M. Kimura,et al.  Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bβ and TSLC1 in neuroblastoma , 2010, Oncogene.

[4]  Y. Reiss,et al.  The E3 Ubiquitin-Ligase Bmi1/Ring1A Controls the Proteasomal Degradation of Top2α Cleavage Complex – A Potentially New Drug Target , 2009, PloS one.

[5]  Yunfu Lin,et al.  Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo. , 2009, Neoplasia.

[6]  A. Hui,et al.  Targeted depletion of BMI1 sensitizes tumor cells to P53-mediated apoptosis in response to radiation therapy , 2009, Cell Death and Differentiation.

[7]  Libing Song,et al.  Bmi-1, stem cells and cancer. , 2009, Acta biochimica et biophysica Sinica.

[8]  J. Chen,et al.  Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression , 2009, Oncogene.

[9]  M. Henriksson,et al.  Embryonal neural tumours and cell death , 2009, Apoptosis.

[10]  K. Matthay,et al.  Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. , 2008, Neoplasia.

[11]  Robert Machold,et al.  Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. , 2008, Cancer cell.

[12]  John T. Dimos,et al.  shRNA knockdown of Bmi-1 reveals a critical role for p21-Rb pathway in NSC self-renewal during development. , 2007, Cell stem cell.

[13]  M. Jackson,et al.  Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma. , 2007, European journal of cancer.

[14]  Hongjuan Cui,et al.  Bmi-1 is essential for the tumorigenicity of neuroblastoma cells. , 2007, The American journal of pathology.

[15]  C. Sherr.  Divorcing ARF and p53: an unsettled case , 2006, Nature Reviews Cancer.

[16]  J. Slaton.  Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors , 2006 .

[17]  Oliver Weichenrieder,et al.  Structure and E3‐ligase activity of the Ring–Ring complex of Polycomb proteins Bmi1 and Ring1b , 2006, The EMBO journal.

[18]  U. Kees,et al.  Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. , 2006, Cancer research.

[19]  G. Perilongo,et al.  Childhood solid tumours: a developmental disorder , 2005, Nature Reviews Cancer.

[20]  A. Peaston,et al.  Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[21]  L. Hansford,et al.  N-myc transcription molecule and oncoprotein. , 2004, The international journal of biochemistry & cell biology.

[22]  R. Gilbertson,et al.  Medulloblastoma: signalling a change in treatment. , 2004, The Lancet. Oncology.

[23]  M. Lohuizen,et al.  Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas , 2004, Nature.

[24]  M. Hogarty.  The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification. , 2003, Cancer letters.

[25]  G. Kay,et al.  Patched 1 conditional null allele in mice , 2003, Genesis.

[26]  D. Livingston,et al.  Polyubiquitination of p53 by a Ubiquitin Ligase Activity of p300 , 2003, Science.

[27]  L. Lossi,et al.  In vivo cellular and molecular mechanisms of neuronal apoptosis in the mammalian CNS , 2003, Progress in Neurobiology.

[28]  G. Brodeur.  Neuroblastoma: biological insights into a clinical enigma , 2003, Nature Reviews Cancer.

[29]  Y. Ravindranath,et al.  High frequency of leukemic clones in newborn screening blood samples of children with B-precursor acute lymphoblastic leukemia. , 2002, Blood.

[30]  David R Kaplan,et al.  N-myc Promotes Survival and Induces S-Phase Entry of Postmitotic Sympathetic Neurons , 2002, The Journal of Neuroscience.

[31]  R. Copeland,et al.  Human mdm2 Mediates Multiple Mono-ubiquitination of p53 by a Mechanism Requiring Enzyme Isomerization* , 2001, The Journal of Biological Chemistry.

[32]  J. Niland,et al.  The MDM2 gene amplification database. , 1998, Nucleic acids research.

[33]  G. Mohapatra,et al.  Targeted expression of MYCN causes neuroblastoma in transgenic mice , 1997, The EMBO journal.

[34]  M. Tuchman,et al.  A population-based study of the usefulness of screening for neuroblastoma , 1996, The Lancet.

[35]  R. Ross,et al.  Human neuroblastoma I-type cells are malignant neural crest stem cells. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[36]  M. Sofroniew,et al.  Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. , 1994, Genes & development.

[37]  Anton Berns,et al.  Identification of cooperating oncogenes in Eμ-myc transgenic mice by provirus tagging , 1991, Cell.

[38]  W. Alexander,et al.  Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in Eμ-myc transgenic mice , 1991, Cell.

[39]  A. Rolink,et al.  Long‐term proliferating early pre B cell lines and clones with the potential to develop to surface Ig‐positive, mitogen reactive B cells in vitro and in vivo. , 1991, The EMBO journal.

[40]  Beckwith Jb,et al.  IN SITU NEUROBLASTOMAS: A CONTRIBUTION TO THE NATURAL HISTORY OF NEURAL CREST TUMORS. , 1963 .

[41]  Nunzio Iraci,et al.  Molecular and Cellular Pathobiology Cancer Research p 53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma , 2010 .

[42]  E. Feldman,et al.  Bcl-2 and M-Myc coexpression increases IGF-IR and features of malignant growth in neuroblastoma cell lines. , 2001, Neoplasia.

[43]  T. Curran,et al.  Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. , 2001, Cancer research.

[44]  E. Feldman,et al.  Bcl-2 and N-Myc Coexpression Increases IGF-IR and Features of Malignant Growth in Neuroblastoma Cell Lines , 2001 .

[45]  R A Ross,et al.  Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. , 1989, Cancer research.

[46]  O. Witte,et al.  Long-term culture of murine bone marrow precursors of B lymphocytes. , 1987, Methods in enzymology.